OPKO Health logo

OPKO HealthNASDAQ: OPK

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 November 1995

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.08 B
-69%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
34%vs. sector
-22%vs. 3y high
32%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:58:02 GMT
$1.61+$0.01(+0.62%)

Dividend

No data over the past 3 years
$173.63 M$155.42 M
$173.63 M$24.89 M

Analysts recommendations

Institutional Ownership

OPK Latest News

OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
zacks.com08 November 2024 Sentiment: NEUTRAL

Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.

OPKO Health (OPK) Q3 Earnings Surpass Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago.

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
zacks.com11 October 2024 Sentiment: POSITIVE

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
globenewswire.com07 October 2024 Sentiment: POSITIVE

WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS).

Here's Why You Should Retain OPKO Health Stock in Your Portfolio
zacks.com02 October 2024 Sentiment: POSITIVE

OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
zacks.com08 August 2024 Sentiment: NEUTRAL

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
zacks.com06 June 2024 Sentiment: POSITIVE

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
Zacks Investment Research01 April 2024 Sentiment: POSITIVE

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Zacks Investment Research25 March 2024 Sentiment: POSITIVE

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
Zacks Investment Research28 February 2024 Sentiment: POSITIVE

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

  • 1(current)
  • 2

What type of business is OPKO Health?

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.

What sector is OPKO Health in?

OPKO Health is in the Healthcare sector

What industry is OPKO Health in?

OPKO Health is in the Diagnostics & Research industry

What country is OPKO Health from?

OPKO Health is headquartered in United States

When did OPKO Health go public?

OPKO Health initial public offering (IPO) was on 02 November 1995

What is OPKO Health website?

https://www.opko.com

Is OPKO Health in the S&P 500?

No, OPKO Health is not included in the S&P 500 index

Is OPKO Health in the NASDAQ 100?

No, OPKO Health is not included in the NASDAQ 100 index

Is OPKO Health in the Dow Jones?

No, OPKO Health is not included in the Dow Jones index

When was OPKO Health the previous earnings report?

No data

When does OPKO Health earnings report?

The next expected earnings date for OPKO Health is 27 February 2025